Matrix Laboratories Ltd. (524794.BY) said Tuesday it has received tentative approval from the U.S. Food and Drug Administration for two generic HIV drugs.

Emtricitabine and tenofovir disoproxil fumarate tablets are the generic version of Gilead Sciences Inc.'s (GILD) truvada, the Indian drugmaker said in a statement to the Bombay Stock Exchange.

Truvada, a second-line drug to treat HIV infection, is used when patients develop resistance to initially prescribed treatments or face clinical failures.

-By Satish Sarangarajan; Dow Jones Newswires; +91 22 2288 4212; satish.sarangarajan@dowjones.com